Microarray gene expression data from RET siRNA-mediated knockdown in CDK4/6 inhibitor breast cancer resistant cells

RET is overexpressed in breast cancer cell lines resistant to combined CDK4/6i and endocrine therapy. siRNA-mediated knockdown of RET was performed to identify main pathways altered upon RET-knockdown. We used microarrays to detail the global programme of gene expression following RET knockdown in 2 cell models resistant to combined CDK4/6 inhibitor palbociclib and fulvestrant (MPFR and TPFR). MPFR-ret and TPFR-ret were compared to MPFR-ctrl and TPFR-ctrl, respectively. The gene expression analysis revealed a significant number of genes altered in the knockdown (ret) vs. ctrl Combined palbociclib and fulvestrant resistant cell lines were derived from MCF-7 and T47D cells by long-term treatment with hig concentration of palbociclib and fulvestrant. RET knockdown was performed by chemical transfection with lipofectime with siRNAs targeting RET and scramble siRNA as control. Total RNA from 3 biological replicates of RET-siRNA and control in MPFR and TPFR cells was extracted and arrayed separately in Human Transcriptome Array 2.0 (HTA, Affymetrix).